Skip to content

Hydrogen-Rich Water Supplementation for Adults with Excess Weight

Hydrogen-Rich Water Supplementation in Adults with Excess Weight: A Randomised, Double-Blind, Placebo-Controlled Translational Study

Status
Not yet recruiting
Phases
Unknown
Study type
Interventional
Source
ANZCTR
Registry ID
ACTRN12626001047381
Enrollment
50
Registered
2026-08-26
Start date
2026-09-01
Completion date
2027-02-01
Last updated
2026-08-31

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

None listed

Brief summary

This study will investigate the effects of hydrogen-rich water (HRW) supplementation in adults with excess body weight through a randomised, double-blind, placebo-controlled clinical trial. Participants will consume either HRW or placebo water daily for six months. The study will evaluate changes in body composition, cardiometabolic health, glycaemic control, oxidative stress, inflammation, and gut microbiota composition. In addition, mechanistic analyses will explore the effects of HRW on immune cell function and redox-related pathways. The findings will contribute to understanding the potential role of hydrogen-rich water as a nutritional intervention for improving metabolic health in adults with overweight and obesity.

Interventions

Description: Participants allocated to the intervention group will consume hydrogen-rich water (HRW) daily for 6 months. The intervention will provide approximately 16 mg of molecular hydrogen (H2) per day, administered as approximately 1.0 L of HRW divided into three daily servings (approximately 333 mL per serving). Participants will be instructed to consume one serving in the morning, one in the early afternoon, and one before dinner. The hydrogen-rich water will be prepared using commercia

Description: Participants allocated to the intervention group will consume hydrogen-rich water (HRW) daily for 6 months. The intervention will provide approximately 16 mg of molecular hydrogen (H2) per day, administered as approximately 1.0 L of HRW divided into three daily servings (approximately 333 mL per serving). Participants will be instructed to consume one serving in the morning, one in the early afternoon, and one before dinner. The hydrogen-rich water will be prepared using commercially available hydrogen-generating tablets supplied by the Industry Partner and legally supplied in Australia. Participants will receive detailed written instructions regarding preparation and consumption of the intervention. All intervention materials will be provided by the research team. Delivery and provider: Self-administered oral consumption by participants, with oversight from the study investigators and research staff. Duration and location: 6 months. Participants will consume the intervention at home and attend study visits at baseline and 6 months for clinical assessments and biological sample collection. Compliance monitoring: Compliance will be assessed through participant logs, tablet counts, and regular contact with the research team. Adverse events and any changes to medications or health status will be recorded throughout the study period. Additional notes: Participants will be instructed to maintain their usual diet, physical activity patterns, and prescribed medications throughout the study unless otherwise advised by their healthcare provider.

Sponsors

La Trobe University
Lead SponsorUniversity

Study design

Allocation
Randomised controlled trial
Intervention model
Parallel
Primary purpose
Treatment
Masking
Blinded (masking used) (Subject, Caregiver, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
All
Age
20 Years to 50 Years
Healthy volunteers
No

Inclusion criteria

Adults aged 20–50 years. Body mass index (BMI) greater than 25.0 kg m2 Normal fasting breath hydrogen levels, i.e., up to 15 ppm

Exclusion criteria

Current smokers. Pregnant women. Use of dietary supplements within four weeks before study commencement. Abnormal clinical laboratory values unrelated to the study outcomes. Acute inflammatory or infectious diseases. Unwillingness to attend follow-up assessments or comply with study procedures. Participation in another clinical trial. Planned initiation or modification of major treatments during the study period.

Outcome results

None listed

Source: ANZCTR · Data processed: Sep 19, 2026